CeriBell Director Sells 827 Shares Amid Changing Market Dynamics

On December 2, 2023, Rebecca Robertson, a director at CeriBell, Inc. (NASDAQ: CBLL), sold 827 shares of the company’s stock. The shares were sold at an average price of $16.67, amounting to a total value of $13,786.09. Following this transaction, Robertson now holds 8,388 shares, valued at approximately $139,827.96, reflecting a decrease of 8.97% in her ownership.

The sale was disclosed through a filing with the Securities and Exchange Commission, providing transparency in the company’s stock activities.

CeriBell’s Market Performance

CeriBell’s stock experienced a notable uptick on December 7, 2023, trading at $19.26. The trading volume reached 459,899 shares, significantly exceeding its average volume of 301,834 shares. Over the past 50 days, the stock has maintained a simple moving average of $13.12, while the 200-day moving average stands at $14.37. CeriBell’s debt-to-equity ratio is currently at 0.12, with a current ratio of 12.65 and a quick ratio of 12.25.

In the past year, the stock reached a low of $10.01 and a high of $32.75. With a market capitalization of $714.36 million and a price-to-earnings ratio of -12.73, CeriBell is experiencing significant fluctuations in its stock value.

Recent Earnings and Analyst Projections

On November 4, 2023, CeriBell reported its quarterly earnings, announcing a loss of ($0.37) per share, which exceeded analysts’ consensus estimate of ($0.43) by $0.06. The company’s revenue for the quarter was $22.59 million, surpassing the expected $21.78 million. Despite these positive results, CeriBell continues to grapple with challenges, reflected in a negative return on equity of 29.63% and a net margin of 63.35%. Analysts project that the company will report an earnings per share of ($2.46) for the current fiscal year.

Several institutional investors have recently adjusted their stakes in CeriBell. Deutsche Bank AG increased its holdings by 0.4% in the first quarter, now owning 231,629 shares valued at $4,450,000. Ameritas Investment Partners Inc. raised its position by 97.5% in the second quarter, acquiring an additional 1,256 shares to own 2,544 shares valued at $48,000.

Notably, Tower Research Capital LLC TRC expanded its stake by 353.8%, now holding 2,310 shares worth $43,000. Zurcher Kantonalbank Zurich Cantonalbank also entered a new position in the third quarter, valued at $33,000. Additionally, Rhumbline Advisers increased its holdings by 26.5% during the first quarter, now owning 15,629 shares valued at $300,000.

CeriBell, Inc. is a commercial-stage medical technology company dedicated to enhancing the diagnosis and management of serious neurological conditions. The firm has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform designed to meet the urgent needs of patients in acute care settings.

For ongoing updates and insights about CeriBell and related companies, market enthusiasts can subscribe to daily summaries through MarketBeat’s free newsletter.